Oncorus, Inc. (ONCR)

Market Cap	8.48M
Revenue (ttm)	n/a
Net Income (ttm)	-77.42M
Shares Out	26.10M
EPS (ttm)	-2.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,897
Open	0.344
Previous Close	0.315
Day's Range	0.325 - 0.344
52-Week Range	0.230 - 1.900
Beta	2.86
Analysts	Buy
Price Target	3.32 (+921.85%)
Earnings Date	May 2, 2023

About ONCR

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 2, 2020
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCR

Analyst Forecast

According to 10 analysts, the average rating for ONCR stock is "Buy." The 12-month stock price forecast is $3.32, which is an increase of 921.85% from the latest price.

Price Target

$3.32

(921.85% upside)

Analyst Consensus: Buy